GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Additional Paid-In Capital

Diamyd Medical AB (OSTO:DMYD B) Additional Paid-In Capital : kr885.04 Mil(As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Additional Paid-In Capital?


Diamyd Medical AB's quarterly additional paid-in capital stayed the same from Nov. 2024 (kr632.03 Mil) to Feb. 2025 (kr632.03 Mil) but then increased from Feb. 2025 (kr632.03 Mil) to May. 2025 (kr885.04 Mil).

Diamyd Medical AB's annual additional paid-in capital increased from Aug. 2022 (kr390.51 Mil) to Aug. 2023 (kr460.29 Mil) and increased from Aug. 2023 (kr460.29 Mil) to Aug. 2024 (kr586.35 Mil).

Diamyd Medical AB Additional Paid-In Capital Historical Data

The historical data trend for Diamyd Medical AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Additional Paid-In Capital Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.41 248.90 390.51 460.29 586.35

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 586.36 586.35 632.03 632.03 885.04

Diamyd Medical AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Diamyd Medical AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:SANION OSTO:XSPRAY OSTO:EGTX OSTO:HNSA OSTO:SYNACT OSTO:IBT B OSTO:GENO XSAT:HAMLET B OSTO:VICO OSTO:FLUO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
DYMDF:USA
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Website
https://www.diamyd.com
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines